Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
misprint in my last message. Is now in the FTSE but obviously not 100 but 250
Oh yeah its going to join the Ftse 100.Any idea when at all?
Its elevation to the FTSE100 and its new female CEO who will be in select company in the FTSE (only 7) and who is pruning and paring like mad make for an exciting future. Big article in todays Times
only to the BoD sadly who tend to use the company as personal cash machine.
Thanks for the info, makes sense, a little R&D can go a long way. Keep the Bunsen's burning chaps.
Never had a dividend and been with BTG for 2 years, the cost of R&D is the reason I think. Maybe one day but this is not the type of share to be paying a dividend as it concentrates of growth.
Does btg ever pay out dividends, and if not why not? Will they ever?
Cannot make up my mind to invest further here. Basic problem there is so little info, no PR and this BB is dead quiet by the looks of it.
Price goes up, price goes down - and Tom the cabin-boy smiles and says nothing. Captain Pugwash 1960 something.
One month on and I am still looking for broker upgrades. Is there anybody out there?
Watch for broker upgrades.
<b>BTG plc 17.8% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 15th December 2015</b> BTG plc with EPIC/TICKER LON:BTG has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 755 GBX on its stock. This would imply the analyst believes there is now a potential upside of 17.8% from the opening price of 641 GBX. Over the last 30 and 90 trading days the company share price has increased 95.5 points and decreased 3 points respectively. BTG plc LON:BTG has a 50 day moving average of 584.88 GBX and the 200 Day Moving Average price is recorded at 669.43 GBX. The 1 year high share price is 835.87 GBX while the year low share price is currently 504 GBX. There are currently 382,957,017 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,454,754,479 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
<b>BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase & Co. December 15th, 2015 • 0 comments • Filed Under • by ABMN Staff</b> BTG plc logoBTG plc (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat.com reports. Several other research firms have also issued reports on BTG. Jefferies Group lowered their price target on shares of BTG plc from GBX 950 ($14.32) to GBX 850 ($12.81) and set a “buy” rating on the stock in a research report on Thursday, September 17th. Stifel Nicolaus reissued a “hold” rating on shares of BTG plc in a research report on Monday. Deutsche Bank boosted their price target on shares of BTG plc from GBX 750 ($11.30) to GBX 755 ($11.38) and gave the company a “buy” rating in a research report on Monday. Finally, Panmure Gordon lowered their price target on shares of BTG plc from GBX 1,035 ($15.60) to GBX 800 ($12.06) and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 779.20 ($11.74). BTG plc (LON:BTG) opened at 623.50 on Tuesday. The company’s market cap is GBX 2.38 billion. The company has a 50-day moving average of GBX 583.22 and a 200 day moving average of GBX 626.33. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 835.87. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company’s Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.
<b>BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase & Co. December 15th, 2015 • 0 comments • Filed Under • by ABMN Staff</b> BTG plc logoBTG plc (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat.com reports. Several other research firms have also issued reports on BTG. Jefferies Group lowered their price target on shares of BTG plc from GBX 950 ($14.32) to GBX 850 ($12.81) and set a “buy” rating on the stock in a research report on Thursday, September 17th. Stifel Nicolaus reissued a “hold” rating on shares of BTG plc in a research report on Monday. Deutsche Bank boosted their price target on shares of BTG plc from GBX 750 ($11.30) to GBX 755 ($11.38) and gave the company a “buy” rating in a research report on Monday. Finally, Panmure Gordon lowered their price target on shares of BTG plc from GBX 1,035 ($15.60) to GBX 800 ($12.06) and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 779.20 ($11.74). BTG plc (LON:BTG) opened at 623.50 on Tuesday. The company’s market cap is GBX 2.38 billion. The company has a 50-day moving average of GBX 583.22 and a 200 day moving average of GBX 626.33. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 835.87. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company’s Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.
BTG broker views Date Broker Recommendation Price Old target price New target price Notes 15 Dec Deutsche Bank Buy 640.50 755.00 755.00 Reiterates 15 Dec JP Morgan Cazenove Overweight 640.50 - - Reiterates 14 Dec Jefferies International Buy 640.50 850.00 850.00 Reiterates 14 Dec Stifel Hold 640.50 - - Reiterates 14 Dec Deutsche Bank Buy 640.50 750.00 755.00 Reiterates
Deutsche bank is saying buy too http://www.risersandfallers.com/2015/12/15/shares-of-btg-plc-lonbtg-rated-as-buy-by-analysts-at-deutsche-bank/
BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase ... 43 minutes ago ... .......http://www.dakotafinancialnews.com/btg-plc-btg-receives-overweight-rating-from-jpmorgan-chase-co/727199/
<b>BTG gets early approval on overdose antidote</b> Drug developer BTG (BTG) has received approval for its toxicity antidote drug Vistogard three months early. Deutsche Bank analyst Richard Parkes retained his ‘buy’ recommendation and upped his target price to 755p from 750p. The shares fell 1.5p to 623.5p yesterday. ‘Approval by the [US] Food and Drug Administration… provides a welcome positive surprise, coming three months ahead of the expected… action date,’ he said. ‘The decision makes it the only approved emergency treatment for accidental overdose or severe toxicity with the cancer treatments fluorouracil or capecitabine. ‘The drug will be marketed via BTG’s speciality pharmaceuticals division, which sells similar antidote therapies…to US hospitals and emergency rooms. Given synergies with BTG’s existing portfolio and sales force, we expect the launch to require minimal investment.’ http://citywire.co.uk/money/the-expert-view-rolls-royce-hammerson-and-cobham/a867279?ref=citywire-money-latest-news-list#i=3
BTG Broker Updates..... BTG PLC BTG Deutsche Bank Buy 623.50 623.50 755.00 755.00 Reiterates BTG PLC BTG JP Morgan Cazenove Overweight 623.50 623.50 - - Reiterate
<b>BTG plc 19.5% Potential Upside Indicated by Deutsche Bank Posted by: Ruth Bannister 14th December 2015</b> BTG plc with EPIC/TICKER LON:BTG had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 755 GBX on its stock. This indicates the analyst now believes there is a potential upside of 19.5% from today’s opening price of 632 GBX. Over the last 30 and 90 trading days the company share price has increased 85 points and decreased 10.5 points respectively. BTG plc LON:BTG has a 50 day moving average of 585.37 GBX and a 200 Day Moving Average share price is recorded at 670.05 GBX. The 52 week high for the stock is 835.87 GBX while the 52 week low is 504 GBX. There are currently 382,185,498 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,403,258,877 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
BTG...... <b>UPDATE 1 – BTG gets triple dose of good news on new products 14-12-2015 11:21</b> (Adds comment from CEO and analyst, latest shares) LONDON, Dec 14 (Reuters) – Specialist medicine company BTG received a triple dose of good news on Monday as U.S. regulators approved two new treatments and a clinical trial of a novel lung device produced positive results. U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses and tumours, and the success of PneumRx coils in severe emphysema may help counter recent disappointment over sales of BTG's varicose vein treatment Varithena. BTG Chief Executive Louise Makin said the positive developments demonstrated the company was delivering on its strategy to become a world-leading specialist healthcare business. The success of PneumRx coils removes a key remaining risk to the launch of the product in the United States, where it will now be filed for approval in mid-2016. Although Deutsche Bank analyst Richard Parkes said the benefit appeared only modest in the PneumRx coils study, as measured by the main outcome, secondary clinical results were strong. BTG shares, which have underperformed in recent months on concerns about sales of Varithena, were 0.8 percent higher at 630 pence by 1110 GMT. (Reporting by Ben Hirschler; Editing by Louise Heavens and Mark Potter) ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net) Keywords: BTG OUTLOOK/
Up!! All aboard
<b>BTG plc Given Overweight Rating at JPMorgan Chase & Co. (BTG) November 17th, 2015</b> BTG plc (LON:BTG)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday, Analyst Ratings Net reports. They presently have a GBX 900 ($13.69) price target on the stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 55.17% from the stock’s previous close. BTG has been the subject of several other research reports. FinnCap reissued a “sell” rating and set a GBX 562 ($8.55) price target on shares of BTG plc in a report on Thursday, August 6th. Stifel Nicolaus increased their target price on shares of BTG plc from GBX 540 ($8.21) to GBX 550 ($8.37) and gave the company a “sell” rating in a report on Thursday, August 6th. Jefferies Group dropped their price objective on shares of BTG plc from GBX 950 ($14.45) to GBX 850 ($12.93) and set a “buy” rating for the company in a research note on Thursday, September 17th. Panmure Gordon restated a “buy” rating and set a GBX 1,035 ($15.74) target price on shares of BTG plc in a research report on Tuesday, October 6th. Finally, Deutsche Bank reiterated a “buy” rating and issued a GBX 940 ($14.30) price target on shares of BTG plc in a report on Wednesday, October 7th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 778.70 ($11.85). BTG plc (LON:BTG) opened at 580.00 on Tuesday. The stock’s market cap is GBX 2.22 billion. BTG plc has a 1-year low of GBX 504.00 and a 1-year high of GBX 835.87. The firm’s 50 day moving average price is GBX 569.17 and its 200-day moving average price is GBX 644.00. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from accredited assets). The Company’s Interventional Medicine section offers a portfolio of interventional medication products that were created to improve the treatment of complex emphysema, liver tumors, acute blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that relieve toxicity and treat rare illnesses. The Organization ‘s Licensing section receives royalties concerning the sales of products which are subject to license agreements and intellectual property between the Company and various partners. The Company’s subsidiary companies comprise BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, amongst others.
BTG BTG PLC Nice to see the P/E multiple coming down here and more importantly the PEG falling below 1 for year 2016 and after which shows the company is in GROWTH MODE. Brokers certainly like the story. BTG PLC FORECASTS 2016 2017 Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p) Panmure Gordon 16-11-15 BUY 86.00 20.10 137.00 30.40 Edison 12-11-15 None 81.00 19.10 104.50 21.00 Shore Capital [A] 02-11-15 BUY Investec Securities 25-09-15 BUY 95.60 20.25 138.40 27.44 Peel Hunt LLP 24-07-15 BUY 84.39 18.58 110.56 22.91 Numis Securities Ltd [R] 15-07-15 HOLD 103.10 20.00 142.60 27.70 Westhouse Securities 18-12-14 BUY 2016 2017 Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p) Consensus 83.68 19.77 132.64 25.92 1 Month Change -5.47 -0.20 -5.67 -0.04 3 Month Change -6.65 0.51 14.19 3.36 Notes to forecasts (02 Apr 2015) A flag refers to outlook GROWTH 2015 (A) 2016 (E) 2017 (E) Norm. EPS 7.71% 99.44% 31.11% DPS % % % INVESTMENT RATIOS 2015 (A) 2016 (E) 2017 (E) EBITDA £72.20m £82.17m £128.00m EBIT £38.30m £m £m Dividend Yield 0.00% % % Dividend Cover x x x PER 58.52x 29.34x 22.38x <b>PEG 7.59f 0.30f 0.72f</b> Net Asset Value PS -6.05p p p
17 Nov 2015 BTG PLC BTG JP Morgan Cazenove Overweight 580.00 580.00 900.00 900.00 Reiterates SP Target 900p